RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)
RP-A701-0125
Phase 1 gene_therapy active
Quick answer
RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) for Dilated Cardiomyopathy (DCM) is a Phase 1 program (gene_therapy) at ROCKET PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ROCKET PHARMACEUTICALS, INC.
- Indication
- Dilated Cardiomyopathy (DCM)
- Phase
- Phase 1
- Modality
- gene_therapy
- Status
- active